Short answer
Regeneron Pharmaceuticals (REGN) filed an 8-K current report with the SEC on July 30, 2026 reporting Item 2.02 (Results of Operations and Financial Condition), Item EX-99.1 (Exhibit EX-99.1). Q2 2026 financial and operating results announced for quarter ended June 30, 2026.
Regeneron Pharmaceuticals 8-K event analysis
AI summary of each reported item and its exhibits
Item 2.02 · Results of Operations and Financial Condition
- Q2 2026 financial and operating results announced for quarter ended June 30, 2026
- Press release furnished as Exhibit 99.1, containing the substantive earnings details
- Results disclosure enables assessment of quarterly performance and operating trends
Item EX-99.1 · Exhibit EX-99.1
- Q2 revenue $4.291B, up 17%; non-GAAP EPS $14.29, up 11%, signaling broad commercial momentum
- Dupixent collaboration sales reached $6.0B globally; Sanofi collaboration revenue rose 51% to $2.174B
- Sanofi Development Balance fully repaid, enabling a meaningful collaboration-profit step-up beginning Q3
- EYLEA HD U.S. sales rose 52% to $596M, partly offsetting legacy EYLEA sales decline of 45% to $412M
- 2026 guidance improved for gross margin, R&D, SG&A, capital expenditures, and tax rate; $2.5B remains for buybacks
Generated from the filing text and exhibits; verify against the original. What 8-K item codes mean
Other Regeneron Pharmaceuticals 8-K filings
Get the next REGN 8-K as it lands
Follow REGN for push alerts, or ask the research agent what this filing means.